NO974258D0 - IL-17-reseptor - Google Patents

IL-17-reseptor

Info

Publication number
NO974258D0
NO974258D0 NO974258A NO974258A NO974258D0 NO 974258 D0 NO974258 D0 NO 974258D0 NO 974258 A NO974258 A NO 974258A NO 974258 A NO974258 A NO 974258A NO 974258 D0 NO974258 D0 NO 974258D0
Authority
NO
Norway
Prior art keywords
receptors
receptor
isolated
ctla
inhibit
Prior art date
Application number
NO974258A
Other languages
English (en)
Other versions
NO974258L (no
Inventor
Zhengbin Yao
Melanie K Spriggs
William C Fanslow
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27021039&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO974258(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO974258D0 publication Critical patent/NO974258D0/no
Publication of NO974258L publication Critical patent/NO974258L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO974258A 1995-03-23 1997-09-15 IL-17-reseptor NO974258L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41053595A 1995-03-23 1995-03-23
US53876595A 1995-08-07 1995-08-07
PCT/US1996/004018 WO1996029408A1 (en) 1995-03-23 1996-03-21 Il-17 receptor

Publications (2)

Publication Number Publication Date
NO974258D0 true NO974258D0 (no) 1997-09-15
NO974258L NO974258L (no) 1997-11-24

Family

ID=27021039

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974258A NO974258L (no) 1995-03-23 1997-09-15 IL-17-reseptor

Country Status (15)

Country Link
US (9) US5869286A (no)
EP (1) EP0817847B2 (no)
JP (1) JP4373495B2 (no)
KR (1) KR100467998B1 (no)
AT (1) ATE279517T1 (no)
AU (1) AU696775B2 (no)
CA (1) CA2215394C (no)
DE (1) DE69633617T3 (no)
DK (1) DK0817847T4 (no)
ES (1) ES2229264T5 (no)
MX (1) MX9707021A (no)
NO (1) NO974258L (no)
NZ (1) NZ306653A (no)
PT (1) PT817847E (no)
WO (1) WO1996029408A1 (no)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274711B1 (en) * 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
DK0817847T4 (da) * 1995-03-23 2009-10-05 Immunex Corp IL-17-receptor
US6680057B1 (en) * 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
WO1997004097A2 (en) * 1995-07-19 1997-02-06 Genetics Institute, Inc. Human ctla-8 and uses of ctla-8-related proteins
US6902735B1 (en) 1995-07-19 2005-06-07 Genetics Institute, Llc Antibodies to human IL-17F and other CTLA-8-related proteins
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
DE69739375D1 (de) * 1996-11-27 2009-06-04 Immunex Corp Verfahren zur regulierung der stickstoffmonoxid-erzeugung
US7005412B1 (en) * 1996-11-27 2006-02-28 Immunex Corporation Method of treating ulcerative colitis and Crohn's disease using IL-17 receptor proteins
US6579520B2 (en) * 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
EP1015488B1 (en) * 1997-09-17 2009-09-09 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
US6482923B1 (en) * 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
NZ505710A (en) * 1997-12-22 2003-03-28 Stiftelsen Universitetsforskni Human Fc receptor genotypes that correspond to the benign/non benign nature of selected autoimmune diseases
WO1999035263A2 (en) * 1998-01-09 1999-07-15 Immunex Corporation Il-17rh dna and polypeptides
US20050147609A1 (en) * 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
PT1076703E (pt) 1998-05-15 2007-10-10 Genentech Inc ''utilizações terapêuticas de polipéptido homólogos de il-17''
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US8133734B2 (en) * 1999-03-16 2012-03-13 Human Genome Sciences, Inc. Kit comprising an antibody to interleukin 17 receptor-like protein
AU781547B2 (en) * 1999-04-14 2005-05-26 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft
WO2000064327A2 (en) * 1999-04-26 2000-11-02 Duke University Inhibition of complement action
US6936424B1 (en) 1999-11-16 2005-08-30 Matritech, Inc. Materials and methods for detection and treatment of breast cancer
JP2016047051A (ja) * 1999-12-23 2016-04-07 ジェネンテック， インコーポレイテッド Ｉｌ−１７相同的ポリペプチドとその治療上の用途
EP1897947B1 (en) * 1999-12-23 2012-01-18 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
AU2590901A (en) * 1999-12-23 2001-07-03 Genentech Inc. Il-17 homologous polypeptides and therapeutic uses thereof
JP2003526370A (ja) * 2000-03-16 2003-09-09 アムジェン インコーポレーテッド Ｉｌ−１７レセプター様分子およびその使用
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
MXPA02011617A (es) * 2000-05-24 2003-03-10 Schering Corp Proteinas de mamiferos receptoras, reactivosy metodos relacionados.
EP3190126A1 (en) 2000-05-26 2017-07-12 Immunex Corporation Use of interleukin-4 receptor (il-4r) antibodies and compositions thereof
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020146763A1 (en) * 2000-07-06 2002-10-10 Zeren Gao Murine cytokine receptor
EP1332211A2 (en) * 2000-07-26 2003-08-06 ZymoGenetics, Inc. Human cytokine receptor
MXPA03003407A (es) * 2000-10-18 2004-05-04 Immunex Corp Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17.
AU2002225714A1 (en) * 2000-11-10 2002-05-21 The Regents Of The University Of California Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage
PL376536A1 (pl) 2002-08-28 2006-01-09 Immunex Corporation Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego
EP1576137A4 (en) * 2002-10-29 2010-06-30 Genentech Inc COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
JP4441170B2 (ja) * 2002-11-28 2010-03-31 独立行政法人理化学研究所 Ｓ１２リボソームタンパク質に変異を有する大腸菌細胞抽出液及びそれを用いる無細胞系によるタンパク質の製造方法
DK1670511T3 (da) * 2003-09-15 2009-11-23 Res Dev Foundation Cripto-antagonisme af activin- og TGF-B-signalering
JP2008501035A (ja) * 2004-05-28 2008-01-17 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 妊孕性関連障害の治療におけるｉｌ−１７の使用
WO2005123778A2 (en) 2004-06-10 2005-12-29 Zymogenetics, Inc. Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US20060068434A1 (en) * 2004-09-21 2006-03-30 Jay Stoerker Methods and compositions for detecting cancer using components of the U2 spliceosomal particle
BRPI0516603A (pt) * 2004-10-18 2008-09-16 Zymogenetics Inc receptor solúvel isolado, anticorpo ou fragmento de anticorpo, e, métodos para tratar uma doença imuno-mediada em um paciente em necessidade de tal tratamento, para reduzir a inflamação mediada pela il-17c, para tratar um mamìfero afligido com uma doença inflamatória, e para tratar uma condição patológica em um paciente associada com a atividade de zcytor21
JP4868731B2 (ja) 2004-11-17 2012-02-01 独立行政法人理化学研究所 哺乳動物培養細胞由来の無細胞タンパク質合成システム
JP4590249B2 (ja) * 2004-11-17 2010-12-01 独立行政法人理化学研究所 糖タンパク質合成用の無細胞タンパク質合成システム
JP4787488B2 (ja) * 2004-11-19 2011-10-05 独立行政法人理化学研究所 直鎖状鋳型ｄｎａを用いた無細胞タンパク質合成方法及びそのための細胞抽出液
JP2008532493A (ja) * 2005-02-14 2008-08-21 ワイス Ｉｌ−１７ｆとｉｌ−１７ｒとの間の相互作用の特性解析
AR052289A1 (es) * 2005-02-14 2007-03-07 Wyeth Corp Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il-17f y sus usos
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
US20080311078A1 (en) 2005-06-14 2008-12-18 Gokarn Yatin R Self-Buffering Protein Formulations
EP1933869B1 (en) 2005-09-01 2009-10-14 Schering Corporation Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
US20070249533A1 (en) 2005-09-28 2007-10-25 Levin Steven D Il-17a and il-17f antagonists and methods of using the same
US20070197441A1 (en) * 2006-02-10 2007-08-23 Rixon Mark W Truncated il-17ra soluble receptor and methods of using in inflammation
US7622116B2 (en) 2006-02-10 2009-11-24 Zymogenetics, Inc. Method of treating inflammation using soluble IL-17RCX4
AU2007261019A1 (en) * 2006-06-19 2007-12-27 Wyeth Methods of modulating IL-22 and IL-17
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
FR2908999B1 (fr) * 2006-11-29 2012-04-27 Biomerieux Sa Nouveau medicament destine a l'inhibition, la prevention ou le traitement de la polyarthrite rhumatoide.
FR2910324B1 (fr) * 2006-12-21 2009-03-06 Biomerieux Sa Nouveau medicament pour le traitement d'un cancer gastrique
EP2417974A1 (en) 2007-02-28 2012-02-15 Schering Corporation Combination therapy for treatment of immune disorders
WO2008118930A1 (en) * 2007-03-26 2008-10-02 Zymogenetics, Inc. Soluble il-17ra/rc fusion proteins and related methods
CL2008000883A1 (es) * 2007-03-28 2008-10-03 Wyeth6 3 Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a
WO2008131315A2 (en) * 2007-04-20 2008-10-30 Amgen Inc. Jacquelinidentification and method for using the pre-ligand assembly domain of the il-17 receptor
JP2010534664A (ja) * 2007-07-23 2010-11-11 セントコア・オーソ・バイオテツク・インコーポレーテツド Ｉｌ−１７拮抗薬を用いた線維症関連疾患治療の方法及び組成物
WO2009042162A2 (en) * 2007-09-25 2009-04-02 Genzyme Corporation Compositions and methods for inhibiting interleukin pathways
EP2213747B1 (en) * 2007-11-05 2021-06-30 Riken Method for producing membrane protein
JP2011514335A (ja) * 2008-02-21 2011-05-06 アムジェン インコーポレイテッド Ｉｌ−１７ｒａ−ｉｌ−１７ｒｂアンタゴニストおよび該アンタゴニストの使用
CA2721713C (en) 2008-05-05 2019-07-09 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
EP2166358A1 (en) * 2008-09-17 2010-03-24 Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron Differential diagnostic biomarkers of stroke mimicking conditions and methods of use thereof
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
WO2010108153A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Carrier immunoglobulins and uses thereof
MX348013B (es) 2009-05-05 2017-05-23 Novimmune Sa Anticuerpos anti il-17f y metodos de uso de los mismos.
US20130064788A1 (en) * 2009-10-10 2013-03-14 Eleven Biotherapeutics, Inc. Il-17 family cytokine compositions and uses
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
WO2011088120A1 (en) 2010-01-15 2011-07-21 Amgen Inc. Antibody formulation and therapeutic regimens
EP2552967A4 (en) 2010-04-02 2014-10-08 Amunix Operating Inc BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
CN103339145A (zh) 2010-09-22 2013-10-02 安姆根有限公司 运载体免疫球蛋白及其用途
AU2012245231B2 (en) 2011-04-20 2016-10-13 Amgen Inc. Autoinjector apparatus
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
JP6768501B2 (ja) 2013-03-15 2020-10-14 アムゲン・インコーポレーテッド 薬物カセット、自動注入機、および自動注入機システム
CA2904725C (en) 2013-03-15 2022-04-12 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
US20170174772A1 (en) 2014-03-31 2017-06-22 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
US11618777B2 (en) 2015-07-31 2023-04-04 Shigeyuki Yokoyama Method of manufacturing membrane protein and utilization thereof
EP3452598A4 (en) 2016-05-06 2020-04-29 Exicure, Inc. LIPOSOMAL SPHERIC NUCLEIC ACID (SNA) CONSTRUCTS WITH ANTISENSE OLIGONUCLEOTIDES (ASO) FOR THE SPECIFIC KNOCKDOWN OF INTERLEUKIN-17 RECEPTOR MRNA
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
SG11202002772VA (en) 2017-11-16 2020-04-29 Amgen Inc Autoinjector with stall and end point detection
CN114107385A (zh) 2019-01-17 2022-03-01 百奥赛图(北京)医药科技股份有限公司 人源化转基因动物
EP4028053A1 (en) 2019-09-11 2022-07-20 Bausch Health Ireland Limited Methods of treating nonalcoholic fatty liver disease (nafld) using il-17ra antibody
JP2022176672A (ja) * 2021-05-17 2022-11-30 国立大学法人北海道大学 ペプチド及び医薬用組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5703088A (en) * 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US6274711B1 (en) * 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US6562333B1 (en) * 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
DK0817847T4 (da) * 1995-03-23 2009-10-05 Immunex Corp IL-17-receptor
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
DE69739375D1 (de) * 1996-11-27 2009-06-04 Immunex Corp Verfahren zur regulierung der stickstoffmonoxid-erzeugung
MXPA03003407A (es) * 2000-10-18 2004-05-04 Immunex Corp Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17.

Also Published As

Publication number Publication date
ES2229264T5 (es) 2009-12-17
AU696775B2 (en) 1998-09-17
ATE279517T1 (de) 2004-10-15
JPH11503309A (ja) 1999-03-26
WO1996029408A1 (en) 1996-09-26
DE69633617D1 (de) 2004-11-18
US6100235A (en) 2000-08-08
KR100467998B1 (ko) 2005-11-25
ES2229264T3 (es) 2005-04-16
DE69633617T2 (de) 2005-11-03
EP0817847A1 (en) 1998-01-14
NO974258L (no) 1997-11-24
CA2215394C (en) 2011-04-26
JP4373495B2 (ja) 2009-11-25
US6096305A (en) 2000-08-01
US6072037A (en) 2000-06-06
US6191104B1 (en) 2001-02-20
MX9707021A (es) 1997-11-29
EP0817847B2 (en) 2009-09-09
US20100233186A1 (en) 2010-09-16
DE69633617T3 (de) 2010-05-20
CA2215394A1 (en) 1996-09-26
PT817847E (pt) 2005-02-28
AU5526396A (en) 1996-10-08
DK0817847T3 (da) 2005-02-14
DK0817847T4 (da) 2009-10-05
US20090068737A1 (en) 2009-03-12
US6197525B1 (en) 2001-03-06
EP0817847B1 (en) 2004-10-13
US6072033A (en) 2000-06-06
US5869286A (en) 1999-02-09
NZ306653A (en) 1999-03-29
KR19980703061A (ko) 1998-09-05

Similar Documents

Publication Publication Date Title
DK0817847T4 (da) IL-17-receptor
LU91758I9 (no)
ATE360032T1 (de) Cystein-reiche rezeptoren-train
FI972945A (fi) Antigeenien antamiseen soveltuvia koostumuksia
DZ2026A1 (fr) Compositions vaccinantes.
EP0837927A4 (en) MONOCLONAL MONKEY ANTIBODIES AGAINST HUMANE B7.1 AND / OR B7.2 ANTIGEN, PRIMATIZED DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS
IS4565A (is) 2-methýl-thíenó-bensódíasepín, samsetning til inntöku
FR2705566B1 (fr) Nouvelles compositions pharmaceutiques.
CY1108074T1 (el) Ανοσολογικες μεθοδοι για τη ρυθμιση της μυοστατινης σε σπονδυλωτα
ITRM920476A1 (it) Formulazioni galeniche contenenti ciclosporina.
ATE169031T1 (de) Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor
TR200001218T2 (tr) İkameli karboksamidotiazoller, bunların üretimi ve bunları içeren farmasötik bileşimler.
IT8920486A0 (it) Composizioni farmaceutiche.
DZ1559A1 (fr) Compositions pharmaceutiques.
DE69007908D1 (de) Shampoo-Zusammensetzung.
DE69600598D1 (de) Brennstoffzusammensetzungen
FI916067A (fi) Receptor foer humant interleukin 5.
FR2674755B1 (fr) Nouvelles compositions medicamenteuses immunostimulatrices.
TR199601012A2 (tr) Sampuan terkibi.
TR199800152T1 (xx) Endotelin Resept�r Antagonistleri
BG101849A (en) Bicyclic tachyquinine antagonists, their preparation and use in pharmaceutical compositions
BR9802803A (pt) ação e composições farmacêuticas contendo os mesmos.
DE69300779D1 (de) Verbesserungen an Rohrverbindungen.
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
IT1294932B1 (it) Uso di 2-amminotetraline-6,7 sostituite per la preparazione di composizioni farmaceutiche atte al trattamento di patologie